Table 1.
Patients’ demography and tumor characteristics.
| Characteristics | MiniPDX-guided group (n = 21) | Experimental treatment group (n = 47) | p-value |
|---|---|---|---|
| Age, years | 0.270 | ||
| Median (range) | 62 (28–83) | 63 (32–86) | |
| <65, n (%) | 8 | 20 | |
| ≥65 | 13 | 27 | |
| Sex | 0.612 | ||
| Male | 13 | 26 | |
| Female | 8 | 21 | |
| ECOG PS | 0.560 | ||
| 0–1 | 17 | 35 | |
| 2 | 4 | 12 | |
| Primary gastric tumors size | 0.763 | ||
| Mean (SE), cm | 5.76 (2.35) | 5.49 (2.96) | |
| <5 cm | 9 | 22 | |
| ≥5 cm | 12 | 25 | |
| Differentiation of primary tumor | 0.954 | ||
| Well | 3 | 8 | |
| Moderate | 15 | 32 | |
| Poor | 3 | 7 | |
| T-stage of primary tumor& | 0.934 | ||
| pT1 | 2 | 7 | |
| pT2 | 5 | 11 | |
| pT3 | 11 | 22 | |
| pT 4 | 3 | 7 | |
| N-stage of Primary tumor& | 0.908 | ||
| N0 | 3 | 7 | |
| N1 | 9 | 19 | |
| N2 | 6 | 11 | |
| N3 | 3 | 10 | |
| Number of metastases | 0.634 | ||
| Median (range) | 4 (1–9) | 4 (1–11) | |
| Solitary n (%) | 9 | 22 | |
| 2–5, n (%) | 9 | 15 | |
| >5, n (%) | 3 | 10 | |
| Metastases tumors size | 0.793 | ||
| Median (range), cm | 4.77 (2.18) | 4.06 (2.69) | |
| <5 cm | 10 | 24 | |
| ≥5 cm | 11 | 23 | |
| Metastases lesions location | 0.914 | ||
| Left lobe, n (%) | 5 | 10 | |
| Right lobe, n (%) | 6 | 12 | |
| Both, n (%) | 10 | 25 | |
| Interruption of hepatic hilum | 0.243 | ||
| Yes | 5 | 18 | |
| No | 16 | 29 | |
| Relapse or refractory disease | 0.600 | ||
| Relapse | 9 | 17 | |
| Refractory | 12 | 30 | |
| CEA level* | 0.210 | ||
| Mean ± SE, ng/ml | 47.66 ± 29.06 | 54.01 ± 33.72 | |
| Negative | 4 | 16 | |
| Positive | 17 | 31 | |
| CA199# | 0.349 | ||
| Mean ± SE, U/ml | 3879.2 ± 1823.3 | 4211.3 ± 2201.3 | |
| Negative | 6 | 19 | |
| Positive | 15 | 28 |
&Tumor stage was defined according to the American Joint Committee on Cancer (AJCC) TNM staging system (AJCC 7th edition).
*CEA levels were measured in 16 and 38 patients, respectively, in MiniPDX-guided and experimental treatment groups. A CEA level of <5 ng/ml was considered as negative.
#CA19-9 levels were measured in 17 and 40 patients, respectively, in MiniPDX-guided and experimental treatment groups. A CA19-9 level of <37 U/ml was considered as negative.
CA19-9, carbohydrate antigen 19-9; CEA, carcinoma embryonic antigen; ECOG PS, Eastern Cooperative Oncology Group physical status; PDX, patient-derived xenograft.